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Here, we set out to assess CA9 expression levels by real-time quantitative RT–PCR in breast cancer tissue samples obtained from
253 patients, and correlated those with relapse-free (RFS) survival. The median follow-up time was 75 months (range 2–168
months). CA9 expression was mainly found in high-grade, steroid receptor negative cancer tissues. CA9 levels were not significantly
associated with RFS (P¼0.926, hazard ratio (HR)¼0.99, 95% CI¼0.80–1.22) in the total cohort of 253 patients. In multivariate
analysis with other clinicopathological factors, CA9 (P¼0.018, HR¼0.77, 95% CI¼0.62–0.96), the interaction of adjuvant
chemotherapy with CA9 (P¼0.009, HR¼1.31, 95% CI¼1.07–1.61) and the interaction of adjuvant endocrine therapy with CA9
(Po0.001, HR¼1.41, 95% CI¼1.20–1.66) all contributed significantly to the final model. These results indicate that patients with
low CA9 levels benefit more from adjuvant treatment than do patients with high levels. Thus, the determination of CA9 levels could
aid in the selection of patients who will not benefit from adjuvant therapy, and whose prognosis will more likely improve with other
treatment modalities.
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Hypoxia has long been known to play an important role in the
development of treatment resistance in cancer. Hypoxic cells are
particularly radioresistant (Ho ¨ckel et al, 1996b), but hypoxia has
also been associated with resistance to chemotherapy (Luk et al,
1990). Not only does tumour hypoxia directly attenuate therapy
success, but it also leads to clonal selection of more aggressive cells
leading to poor prognosis, independent of treatment modality
(Ho ¨ckel et al, 1996a; Rofstad, 2000). Molecular mechanisms
underlying the association between hypoxia and treatment
resistance are poorly understood. Identifying factors associated
with treatment outcome in cancer patients provides the possibility
to perform more effective therapies and offers targets for treatment
resistance modification.
Carbonic anhydrase (CA)-9 is one of the best-known genes
associated with tumour cell hypoxia, and is quickly and extensively
upregulated under hypoxic conditions (Wykoff et al, 2000; Lal et al,
2001). CAs are a family of zinc metalloenzymes. The human gene
product CA IX (MN or G250), originally identified in HeLa cells,
catalyses the hydration of carbon dioxide to carbonic acid. CA IX
is a transmembrane glycoprotein of 58/54kDa, encoded by a 1.5kb
mRNA with exon 1 encoding a signal peptide and a proteoglycan-
related region. Exons 2–8 code for a CA domain with a highly
conserved active site. Exons 10 and 11 encode a transmembrane
anchor and an intracytoplasmic tail, respectively (Opavsky et al,
1996). Studies have reported on CA IX expression in several
carcinomas such as renal cell (Liao et al, 1997), colorectal (Saarnio
et al, 1998), nonsmall lung (Vermylen et al, 1999; Giatromanolaki
et al, 2001), cervical (Olive et al, 2001), bladder (Turner et al, 2002)
and nasopharyngeal carcinoma (Hui et al, 2002), while being
absent from most normal tissues. Its role in tumour growth and
disease progression has been attributed to its effect on reducing
pericellular pH in response to hypoxia, thereby facilitating the
breakdown of extracellular matrix (Giatromanolaki et al, 2001),
but CA IX might also play a role in cell–cell communications.
In ductal carcinoma in situ of the breast, CA IX can be detected
(Wykoff et al, 2001). So far, only a few papers have addressed the
expression of CA IX in invasive breast cancer (Chia et al, 2001;
Bartosova et al, 2002). Here, we set out to assess CA9 expression
levels in a large number of samples by real-time quantitative RT–
PCR, and correlated those with relapse-free survival (RFS) in
patients who were treated with surgery alone, or with additional
radio-, chemo- and/or endocrine therapy. Thereby, we aimed at
identifying a potential predictive value of CA9 for treatment
success in breast cancer.
MATERIAL AND METHODS
Patients
Breast cancer tissue samples were obtained from 253 patients with
unilateral, operable breast cancer who underwent resection of their
primary tumour between February 1987 and December 1997.
Selections were made based on availability of frozen tissue from Received 16 January 2003; revised 28 April 2003; accepted 7 May 2003
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oestrogen (ER) and progesterone receptor (PgR) ligand binding
assay for five different hospitals of the Comprehensive Cancer
Center East in the Netherlands. The median age was 60 years
(range 31–88 years). Patients had no previous diagnosis of
carcinoma (with the exception of basal cell carcinoma of the
skin), no distant metastases at the time of diagnosis and no
evidence of disease within 1 month after primary surgery. The
latter patients are excluded because of the likely occurrence in this
group of metastases at the time of primary surgery that escaped
detection. Furthermore, patients receiving neo-adjuvant therapy or
those with carcinoma in situ only were excluded. Patients
underwent modified radical mastectomy (n¼183) or breast-
conserving therapy (n¼70). Postoperative radiotherapy was given
after mastectomy for T3-4 disease or in case of nodal involvement
of X3 nodes (n¼114), and after BCT. Lymph node involvement
was found in 131 patients. Subsequent systemic adjuvant therapy
(85 endocrine therapy, 28 chemotherapy, 14 both) was given based
on the consensus at the time of treatment. In the absence of
involved axillary lymph nodes, patients usually did not receive
adjuvant treatment. When involved axillary lymph nodes were
detected, premenopausal patients received chemotherapy. In the
case of an ER- and/or PgR-positive primary tumour, additional
endocrine therapy was given to these patients. Postmenopausal
patients with involved axillary lymph nodes and ER- and/or PgR-
positive tumours received adjuvant endocrine therapy. If the
primary tumour of these patients was hormone receptor negative,
no adjuvant therapy was given, although in some cases endocrine
therapy was opted for. The median follow-up time was 75 months
(range 2–168 months). Patients were seen (history, physical
examination, routine laboratory investigations) once every 3
months during the first 2 years, once every 6 months for the next
5 years and once a year afterwards. Once a year, X-ray
mammography was made. During follow-up, 93 patients had a
recurrence (20 locoregional, 71 distant metastases and two both)
and 72 patients died of which 55 died due to breast cancer-related
causes, two patients died by other malignancies, 15 patients died
due to unknown causes. Contralateral breast cancer or second
malignancies were not considered recurrent disease.
Tissue processing
After primary surgery, a representative part of tumour was selected
by a pathologist, frozen in liquid nitrogen and processed for
routine ER and PgR ligand binding assay. These assays were
performed as recommended by the European Organisation for
Research and Treatment of Cancer (EORTC). Aliquots of tissue
were kept in liquid nitrogen until RNA isolation.
Immunohistochemistry
From the biopsy material, frozen sections of 5mm were cut and
mounted in poly-L-lysine-coated slides and stored at  801C until
staining. Prior to staining, sections were fixed for 10min in
acetone of 41C and rehydrated in phosphate-buffered saline (PBS).
Between all consecutive incubation procedures, tissue sections
were rinsed in PBS three times for 3min. After rehydration, the
sections were incubated with 5% normal donkey serum (Jackson
Immuno Research Laboratories Inc., West Grove, PA, USA) in
Monoclonal Liquid Diluent Immunostain (MLD, Euro/DPC Inc.,
Llanberis, UK) for 30min at 371C. Subsequently, they were
incubated with mouse anti-human G250 (kindly provided by Dr
Oosterwijk, Department of Urology, University Medical Center
Nijmegen, The Netherlands) 1:50 for 45min at 371C. Next, the
slides were incubated with donkey anti-mouse-alkaline phospha-
tase (alkaline phosphatase-conjugated affine pure donkey anti-
mouse IgG (HþL), Jackson Immuno Research Laboratories Inc.)
1:100 in MLD for 60min at room temperature followed by
incubation with Vector red substrate (Vector Red Alkaline
Phosphatase Substrate Kit I, Vector Laboratories, Burlingame,
CA, USA) for 30min at room temperature and by rinsing in tap
water. Both avidin and biotin were blocked for 15min at room
temperature (Avidine/biotine blocking Kit, Vector Laboratories).
For staining of the vessels in the same tissue, the sections were
incubated in mouse anti-human CD34 (Coulter Immunotech,
Marseille, France) 1:20 in MLD overnight at 41C. After incubation
with donkey anti-mouse-biotin (Jackson ImmunoResearch La-
boratories Inc.) 1:500 in MLD, 60min at room temperature, slides
were incubated with the ABC reagent (Vector ABC-Elite kit
standard, Vector Laboratories) and rinsed in deionised water for at
least 5min. The colour was developed with DAB (liquid DAB
substrate kit, Zymed Laboratories, Inc S. San Francisco, CA, USA)
for 5min at room temperature. After rinsing in tap water, the
sections were counterstained with haematoxylin (Klinipath,
Duiven, The Netherlands) for 30s. Finally, after rinsing in tap
water again the tissue sections were dehydrated and mounted with
KP mounting medium (Klinipath).
RNA extraction
After pulverising by dismembration in liquid nitrogen, total RNA
was isolated from approximately 20mg tissue powder using the
RNeasy mini kit (Qiagen, Hilden, Germany) with on-column
DNase I treatment. The quality of the RNA was checked by
examining ribosomal RNA bands after agarose gel electrophoresis,
and by amplifying b-actin as a control (see below).
Reverse transcription
Reverse transcription was performed using the Reverse Transcrip-
tion System (Promega Benelux BV, Leiden, The Netherlands)
according to the manufacturer’s protocol. After annealing of
random hexamers for 10min at 201C, cDNA synthesis was
performed for 30min at 421C followed by an enzyme inactivation
step for 5min at 951C.
PCR
PCR reactions were carried out using Taqman Universal PCR
master mix (PE Applied Biosystems, Nieuwerkerk a/d IJssel, the
Netherlands) in a final volume of 25ml. In all, 50nM of the CA9
forward primer (50-GAC GCC TGG CCG TGT TG-30), and of the
reverse primer (50-CTG AGC CTT CCT CAG CGA TT-30) and
200nM of the Taqman probe (50-TET-TTC TGG AGG AGG GCC
CGG AAG A-30) were used. Primers were from Biolegio BV
(Malden, The Netherlands) and the Taqman probe from Perkin-
Elmer (PE Applied Biosystems). The assay was designed intron-
spanning using the Primer-Express software package version 1.5
(PE Applied Biosystems). b-Actin was amplified using the Pre-
Developed Assay Reagents Taqman RT–PCR assay from Perkin-
Elmer (PE Applied Biosystems). All amplifications, with denatura-
tion at 951C for 10min, and 40 cycles of 15s at 951C (melting) and
60s at 601C (annealing and elongation), were performed on an ABI
Prism 7700 Sequence detection system (PE Applied Biosystems).
Quantification of unknown samples was performed using the colon
cancer cell-line SW-480 as a calibrator.
Statistical analyses
Statistical analyses were carried out using SPSS 10.0.5 software
(SPSS Benelux BV, Gorinchem, The Netherlands). Differences in
levels of CA9 expression in samples from patients categorised by
clinicopathological characteristics, used as grouping variables,
were assessed with nonparametric Mann–Whitney U or Kruskall–
Wallis testing where appropriate. RFS time (defined as the time
from surgery until diagnosis of recurrent disease) was used as
CA9 predicts breast cancer recurrence
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considered as variable in multivariate analyses, OS time (defined
as the time between date of surgery and death by any cause) was
not considered as end point, as in some patients OS will be
influenced by additional interventions after disease recurrence.
The Cox proportional hazards model was used to assess the
prognostic value of CA9 expression in addition to other
clinicopathological factors. CA9 levels were entered as a log-
transformed continuous variable. An initial analysis is carried out
including all classical clinicopathological factors, with stepwise
removal of variables according to their likelihood ratio, to
establish a base model. To test for treatment interactions,
interaction variables were entered in the model in a second round,
including CA9, the different treatment modalities (radiotherapy,
endocrine therapy and chemotherapy) and their interaction terms
(Altman and Lyman, 1998; Harbeck et al, 2002; Foekens et al,
2003). Two-sided P-values below 0.05 were considered to be
statistically significant. Cases with 484 months of follow-up were
censored at 84 months, because of the rapidly declining number of
patients thereafter. This is because after a certain period of
observation, patients are frequently redirected to their general
practitioner for check-ups and mammography and cease to belong
to the outpatients collective of our breast cancer clinic.
RESULTS
Immunohistochemistry
Frozen breast tumour specimens were stained for CA IX. The
example shown in Figure 1 shows the typical relationship between
membranous CA IX (anti-human G250, red) and surrounding
tumour vasculature (anti-CD34 staining, brown). It could be seen
that CA IX staining intensity increased at increasing distance from
vessels, suggesting an association of CA IX with diffusion limited
hypoxia.
RT–PCR
In six tumour samples, CA9 RT–PCR was negative after 40 rounds
of amplification. In the other 247 samples, levels ranged from
3.4*10
 7 to 4.6*10
 2 in a log-normal distribution (see Figure 2).
CA9 levels did not differ statistically significant with age, nodal
status, menopausal status, tumour size, type of surgery, radio-
therapy or adjuvant systemic treatment (Table 1). CA9 expression
levels were found to differ, however, with histological grading
(higher in grade III compared to grades I/II, P¼0.009) and, most
notably, with steroid hormone receptor status (higher in steroid
receptor negative samples, Po0.001 for both ER and PgR, see
Table 1).
Univariate survival analysis
In univariate Cox regression analysis, younger age (P¼0.018),
higher number of involved lymph nodes (Po0.001), greater
tumour size (P¼0.011) and higher grade (P¼0.018) were
associated with a poorer RFS (Table 2). In contrast to these
factors, C49 levels were not significantly associated with RFS
(P¼0.926, hazard ratio (HR)¼0.99, 95% CI¼0.80–1.22) in the
total cohort of 253 patients for RFS.
Multivariate survival analysis
In multivariate analysis (Table 3), histological grade (P¼0.019)
and number of involved lymph nodes (Po0.001) remained as
factors contributing significantly to RFS. Subsequently, CA9,
treatment modalities and their interactions were entered. CA9
(P¼0.018, HR¼0.77, 95% CI¼0.62–0.96), the interaction of
chemotherapy with CA9 (P¼0.009, HR¼1.31, 95% CI¼1.07–
1.61) and the interaction of endocrine therapy with CA9 (Po0.001,
HR¼1.41, 95% CI¼1.20–1.66) all contributed significantly to the
final model. These results indicate that CA9 levels can be used to
discriminate patients who are more likely to be resistant to
endocrine and/or chemotherapy.
DISCUSSION
Here, we are the first to show that CA9 expression as measured by
real-time RT–PCR is related to poor outcome after adjuvant
treatment in unilateral, invasive breast cancer. Furthermore, CA9
expression is mainly found in high-grade, steroid receptor negative
cancer tissues.
50 M  200 x
Figure 1 Photomicrograph at X200 magnification illustrating the spatial
relationship between CA IX (anti-human G250, red) and tumour
vasculature (anti-CD34 staining, brown). Nuclei appear as magenta blue
(haematoxylin).
−2.00 −3.00 −4.00 −5.00 −6.00 Negative
10Log (CA9/actin)
0
10
20
30
N
u
m
b
e
r
 
o
f
 
s
a
m
p
l
e
s
Figure 2 Distribution of CA9 levels in human breast cancer: six tumour
samples were found to be CA9 negative. The other 247 samples exhibited
a basically log-normal distribution of CA9 levels.
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yOur approach, that is, the quantification of mRNA by real-time
fluorescence RT–PCR, has several advantages over protein
detection by immunohistochemistry (IHC). It has the potential
of quantification over a wide range of levels and is extremely
sensitive. It can be applied to small tissue samples, even after
processing the tissues by powdering using a dismembrator for
steroid hormone receptor assays as we show here. Finally,
antibody-based methods can be less specific, and can be
differentially hampered by post-translational modifications, mak-
ing a proper comparison of data between institutions difficult. On
the other hand, IHC methods can be more easily entered into
routine clinical practice, and give additional information on the
(sub)cellular and tissular expression of CA IX.
A total of 40–50% of the patients with node-positive breast
cancer will develop distant metastases within 5 years after primary
surgery despite the treatment with adjuvant systemic therapy
(EBCTCG, 1996, 1998). Thus, identifying patients who will benefit
from the other, or more intense treatment protocols is clinically
important. CA IX has been related to prognosis and prediction of
radio- and/or chemotherapy success in several types of solid
tumours (Giatromanolaki et al, 2001; Koukourakis et al, 2001;
Loncaster et al, 2001; Hui et al, 2002; Turner et al, 2002). Its
association with prognosis has been reported earlier in breast
cancer (Chia et al, 2001), although this study included patients
treated by adjuvant systemic therapy. The true prognostic value,
however, of a given factor should be assessed in patients in the
absence of adjuvant treatment (Hayes et al, 1998; Henderson and
Patek, 1998; Barratt et al, 2002; Mori et al, 2002). Predictive factors
can be used to predict response or lack of response to a particular
therapy (Mori et al, 2002). Each therapy should be evaluated
independently in patient cohorts defined by a predictive factor
(Henderson and Patek, 1998). This can be best done in a
prospective randomised clinical trial, which is not always feasible.
On the other hand, large retrospective data sets containing
substantial patient numbers with and without therapy are available
for analysis. It is very difficult to draw conclusions on the
predictive value of a marker because treatment decisions with
regard to adjuvant systemic therapy were based primarily on
consensus recommendations at that time, leading to selection bias
etc. However, using multivariate analysis with interaction variables
is one way to establish the predictive value of a factor from
retrospective studies (Altman and Lyman, 1998; Harbeck et al,
2002; Foekens et al, 2003). In the current study, CA9 is shown to be
an independent predictor of RFS after adjuvant treatment in
invasive resectable breast cancer patients, also when corrected for
other clinicopathological factors. Indeed, in multivariate Cox
regression analysis, a highly significant interaction between
Table 1 Categorical distributions of baseline characteristics of patients
and CA9/b-actin levels
Total group
of patients
a
Variable n % of 253
10
 4 CA9/b-actin
median
(interquartile
range) P
Age (years)
o50 57 22.5 1.3 (8.8)
X50 196 77.5 1.6 (6.8) 0.656
c
Nodal status
b
Negative 103 40.7 1.0 (7.2)
1–3 nodes 78 30.8 1.6 (6.2)
X4 nodes 44 17.4 1.3 (7.9) 0.624
d
Menopausal status
Premenopausal 64 25.3 1.3 (8.7)
Postmenopausal 189 74.7 1.6 (6.7) 0.878
c
Tumour size
pT1 66 26.1 1.2 (7.0)
pT2 137 54.2 1.5 (5.8)
pT3+pT4 46 18.2 3.0 (1.6) 0.611
d
Histological grade
I/II 84 33.2 1.1 (2.7)
III 86 34.0 4.2 (18)
Unknown 83 32.8 1.8 (6.6) 0.009
d
ER (fmolmg
 1 protein)
o10 88 34.8 7.2 (27)
X10 161 63.6 0.82 (2.7) o0.001
c
PgR (fmolmg
 1 protein)
o10 103 40.7 6.2 (23)
X10 147 58.1 0.84 (3.1) o0.001
c
Surgery
Mastectomy 183 72.3 1.5 (6.9)
Breast-saving procedure 70 27.7 1.2 (7.1) 0.902
c
Adjuvant radiotherapy
None 68 26.9 1.3 (6.6)
Any 184 72.7 1.5 (7.4) 0.822
c
Adjuvant systemic therapy
None 126 49.8 1.7 (8.2)
Endocrine 85 33.6 1.5 (5.3)
Chemo 28 11.1 1.0 (5.6)
Both 14 5.5 2.8 (15) 0.735
d
aOwing to missing values data do not always add up to 253.
bAll patients with
uncertain number of involved lymph nodes are node positive.
cP for Mann–Whitney
U test.
d P for Kruskal–Wallis test.
Table 2 Univariate Cox regression analysis of prognostic value of
clinicopathological factors and CA9 expression for RFS
Variable HR (95% CI)
a P
Age (years)
o50 1.0
X50 0.56 (0.35–0.91) 0.018
Nodal status
Negative 1.0
1–3 nodes 1.97 (1.1–3.5)
X4 nodes 4.23 (2.3–7.7) o0.001
Menopausal status
Premenopausal
Postmenopausal 0.091
Tumour size
pT1 1.0
pT2 1.95 (1.1–3.6)
pT3+pT4 2.90 (1.5–5.8) 0.011
Histological grade
I/II 1.0
III 2.24 (1.3–3.9)
Unknown 1.59 (0.8–2.9) 0.018
ER (fmolmg
 1 protein)
o10
X10 0.297
PgR (fmolmg
 1 protein)
o10
X10 0.485
Surgery
Mastectomy
Breast-saving procedure 0.051
Adjuvant radiotherapy
None
Any 0.114
Adjuvant systemic therapy
None
Endocrine
Chemo
Both 0.680
CA9 expression continuous 0.99 (0.80–1.22) 0.926
aHazard ratio (95% CI).
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be established.
Hypoxia is thought to be involved in the development of a radio-
or chemotherapy-resistant phenotype of solid tumours. The
evidence so far on an association of hypoxia, or factors such as
CA9 that are induced by hypoxia, with resistance to endocrine
therapy, however, is scarce. Hypoxia has been shown to lead to
hormone insensitivity by ER degradation in breast cancer cell lines
(Kurebayashi et al, 2001; Stoner et al, 2002). The level of VEGF,
which is also induced under hypoxic conditions (Wykoff et al,
2000; Lal et al, 2001), predicts relapse in patients with breast
cancer receiving adjuvant endocrine therapy more significantly
than after polychemotherapy (Gasparini et al, 1999; Linderholm
et al, 2000). Here, we show that hypoxia-associated CA9 expression
is highest in high-grade, ER-negative breast tumours, which is in
line with some (Chia et al, 2001), but not all (Bartosova et al, 2002),
earlier studies. Interestingly, the latter study on CA9 in breast
cancer (Bartosova et al, 2002) reported a, albeit weak, correlation
with Her2/neu, which is known to be associated with the
acquirement of hormone insensitivity in breast tumours. Thus,
either the reversed correlation between CA9 and ER status, or its
positive correlation with Her2/neu, could explain the endocrine
therapy resistance in tumours expressing high levels of CA9.
In conclusion, we describe here that CA9 is detectable in breast
tumours and is associated with resistance to both adjuvant
chemotherapy and endocrine therapy. Thus, CA9 could aid in
the selection of patients who will not benefit from adjuvant therapy
and whose prognosis will more likely improve with other
treatment modalities.
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Table 3 Multivariate
a Cox regression analysis
Variable HR (95% CI)
b P
Base model
Age (years) 0.146
X50 vs o50 0.61 (0.31–1.19)
Tumour size 0.140
pT2 vs pT1 1.95 (0.98–3.86)
pT3+4 vs pT1 1.96 (0.90–4.28)
Histological grade 0.019
III vs I/II 2.20 (1.21–4.03)
No. of involved lymph nodes o0.001
1–3 vs node negative 6.27 (2.89–13.6)
X4 vs node negative 13.1 (6.12–27.9)
ER status
c 0.852
Positive vs negative 1.08 (0.49–2.39)
PgR status
c 0.858
Positive vs negative 0.96 (0.58–1.58)
Additions to model
CA9 0.018
Log-transformed 0.77 (0.62–0.96)
Adjuvant radiotherapy 0.128
Yes vs no 0.60 (0.31–1.16)
Adjuvant chemotherapy 0.828
Yes vs no 0.76 (0.06–9.25)
Adjuvant endocrine therapy 0.889
Yes vs no 1.15 (0.17–7.96)
Interaction, radiotherapy  CA9 0.624
Yes and log-transformed vs no and
log-transformed
0.89 (0.54–1.44)
Interaction, chemotherapy  CA9 0.009
Yes and log-transformed vs no and
log-transformed
1.31 (1.07–1.61)
Interaction, endocrine therapy  CA9 o0.001
Yes and log-transformed vs no and
log-transformed
1.41 (1.20–1.66)
The analysis was conducted in two blocks. Firstly, a model including all established
clinicopathological factors was fitted. In a second block, the contributions of CA9 (as a
continuous, log-transformed variable), treatment and interactions were investigated.
aThe final multivariate model included 220 patients.
bHazard ratio (95% CI) of
multivariate analysis.
cCut-off point used for ER and PgR, 10fmolmg
 1 protein.
REFERENCES
Altman DG, Lyman GH (1998) Methodological challenges in the evaluation
of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289–
303
Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K,
Quirke P, UKCCCR AXIS trial collaborators (2002) DNA markers
predicting benefit from adjuvant fluorouracil in patients with colon
cancer: a molecular study. Lancet 360: 1381–1391, doi: 10.1016/S0140-
6736(02)11402-4
Bartosova M, Parkkila S, Pohlodek K, Karttunen TJ, Galbavy S, Mucha V,
Harris AL, Pastorek J, Pastorekova S (2002) Expression of carbonic
anhydrase IX in breast is associated with malignant tissues and is related
to overexpression of c-erbB2. J Pathol 197: 314–321, doi: 10.1002/
path.1120
Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC,
Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-
regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J
Clin Oncol 19: 3660–3668
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (1996)
Tamoxifen for early breast cancer: an overview of the randomised trials.
Lancet 351: 1451–1467, doi: 10.1016/S0140-6736(97)11423-4
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (1998) Poly-
chemotherapy for early breast cancer: an overview of the randomised
trials. Lancet 352: 930–942, doi:10.1016/S0140-6736(98)03301-7
Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M
(2003) The prognostic value of polymorphonuclear leukocyte elastase in
patients with primary breast cancer. Cancer Res 63: 337–341
Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E,
Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M
(1999) Clinical relevance of vascular endothelial growth factor and
thymidine phosphorylase in patients with node-positive breast cancer
treated with either adjuvant chemotherapy or hormone therapy. Cancer J
Sci Am 5: 101–111
Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC,
Gatter KC, Harris AL (2001) Expression of hypoxia-inducible
carbonic anhydrase-9 relates to angiogenic pathways and indepen-
dently to poor outcome in non-small cell lung cancer. Cancer Res 61:
7992–7998
Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Kruger A,
Kiechle M, Janicke F, Schmitt M, Foekens JA (2002) Enhanced benefit
from adjuvant chemotherapy in breast cancer patients classified high-
risk according to urokinase-type plasminogen activator (uPA) and
plasminogen activator inhibitor type 1 (n¼3424). Cancer Res 62: 4617–
4622
Hayes DF, Trock B, Harris AL (1998) Assessing the clinical impact of
prognostic factors: when is ‘‘statistically significant’’ clinically useful?
Breast Cancer Res Treat 52: 305–319
Henderson IC, Patek AJ (1998) The relationship between prognostic and
predictive factors in the management of breast cancer. Breast Cancer Res
Treat 52: 261–288
Ho ¨ckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996a)
Association between tumor hypoxia and malignant progression in
advanced cancer of the uterine cervix. Cancer Res 56: 4509–4515
CA9 predicts breast cancer recurrence
PN Span et al
275
British Journal of Cancer (2003) 89(2), 271–276 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yHo ¨ckel M, Schlenger K, Mitze M, Schaffer U, Vaupel P (1996b) Hypoxia and
radiation response in human tumors. Semin Radiat Oncol 6: 3–9
Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo
PM, Huang DP, Gatter KC, Johnson PJ, Harris AL (2002) Coexpression of
hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and
vascular endothelial growth factor in nasopharyngeal carcinoma and
relationship to survival. Clin Cancer Res 8: 2595–2604
Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J,
Wykoff CC, Gatter KC, Harris AL (2001) Hypoxia-regulated carbonic
anhydrase-9 (CA9) relates to poor vascularization and resistance of
squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer
Res 7: 3399–33403
Kurebayashi J, Otsuki T, Moriya T, Sonoo H (2001) Hypoxia reduces
hormone responsiveness of human breast cancer cells. Jpn J Cancer Res
92: 1093–1101
Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL,
Kaanders JH, van der Kogel AJ, Riggins GJ (2001) Transcriptional
response to hypoxia in human tumors. J Natl Cancer Inst 93: 1337–1343
Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ (1997) Identification of
the MN/CA9 protein as a reliable diagnostic biomarker of clear cell
carcinoma of the kidney. Cancer Res 57: 2827–2831
Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B,
Henriksson R (2000) Correlation of vascular endothelial growth factor
content with recurrences, survival, and first relapse site in primary node-
positive breast carcinoma after adjuvant treatment. J Clin Oncol 18:
1423–1431
Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC,
Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase
(CA IX) expression, a potential new intrinsic marker of hypoxia:
correlations with tumor oxygen measurements and prognosis in locally
advanced carcinoma of the cervix. Cancer Res 61: 6394–6399
Luk CK, Veinot-Drebot L, Tjan E, Tannock IF (1990) Effect of transient
hypoxia on sensitivity to doxorubicin in human and murine cell lines. J
Natl Cancer Inst 82: 684–692
Mori I, Yang Q, Kakudo K (2002) Predictive and prognostic markers for
invasive breast cancer. Pathol Int 52: 186–194
Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA,
Lerman MI, Stanbridge EJ (2001) Carbonic anhydrase 9 as an
endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61:
8924–8929
Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada
J, Kettmann R, Pastorek J (1996) Human MN/CA9 gene, a novel member
of the carbonic anhydrase family: structure and exon to protein domain
relationships. Genomics 33: 480–487, doi: 10.1006/geno. 1996.0223
Rofstad EK (2000) Microenvironment-induced cancer metastasis. Int J
Radial Biol 76: 589–605
Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J,
Kairaluoma MI, Karttunen TJ (1998) Immunohistochemical study of
colorectal tumors for expression of a novel transmembrane carbonic
anhydrase, MN/CA IX, with potential value as a marker of cell
proliferation. Am J Pathol 153: 279–285
Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S (2002)
Hypoxia induces proteasome-dependent degradation of estrogen recep-
tor alpha in ZR-75 breast cancer cells. Mol Endocrinol 16: 2231–2242,
doi:10.1210/me.2001-0347
Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J,
Ratcliffe PJ, Cranston D, Harris AL (2002) The hypoxia-inducible genes
VEGF and CA9 are differentially regulated in superficial vs
invasive bladder cancer. Br J Cancer 86: 1276–1282, doi: 10.1038/sj/
bjc/6600215
Vermylen P, Roufosse C, Burny A, Verhest A, Bosschaerts T, Pastorekova S,
Ninane V, Sculier JP (1999) Carbonic anhydrase IX antigen differentiates
between preneoplastic malignant lesions in non-small cell lung
carcinoma. Eur Respir J 14: 806–811
Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, Pastorek
J, Sly WS, Ratcliffe P, Harris AL (2001) Expression of the hypoxia-
inducible and tumor-associated carbonic anhydrases in ductal carcino-
ma in situ of the breast. Am J Pathol 158: 1011–1019
Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A,
Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ,
Harris AL (2000) Hypoxia-inducible expression of tumor-associated
carbonic anhydrases. Cancer Res 60: 7075–7083
CA9 predicts breast cancer recurrence
PN Span et al
276
British Journal of Cancer (2003) 89(2), 271–276 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y